– New revumenib and Niktimvo™ clinical data will be highlighted at 66th ASH Annual Meeting –
– mNPM1 AML topline data from AUGMENT-101 expected in 4Q24; potential sNDA filing in 1H25 –
– Revumenib NDA in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 –
– Niktimvo approved by U.S. FDA for treatment of chronic GVHD after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg –
– $350 million royalty funding agreement for Niktimvo expected to fund Company through profitability –
– Company to host a conference call today at 4:30 p.m. ET –
, /PRNewswire/ — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the quarter ended September 30, 2024, and provided a business update.
“This has been a historic period for Syndax as we transitioned to …